Proton pump inhibitors with antibiotics

A. One-week triple therapy regimes combining a proton pump inhibitor with two antibiotics chosen from amoxicillin, clarithromycin and metronidazole are effective in about 90% of cases. 

Eradication therapy with a proton pump inhibitor-based three-drug regimen should be considered for all patients who test positive for HP and have an active ulcer or a documented history of either an ulcer or ulcer-related complication. Different antibiotics should be used if a second course of HP eradication therapy is required. 

The incidence of community-associated C. difficile infection (defined as occurring in patients not hospitalized in the year prior to diagnosis) is increasing.36 In addition to antibiotic use, community-associated C. difficile cases are associated with the use of gastric acid suppressive agents (e.g., proton pump inhibitors and H2-receptor antagonists). 

Shmuely, H., Yahav, J., Samra, Z., Chodick, G., Koren, R., Niv, Y., and Ofek, I. (2007). Effect of cranberry juice on eradication of Helicobacter pylori in patients treated with antibiotics and a proton pump inhibitor. Mol. Nutr. Food Res. 51, 746-751. 

There is increasing evidence that eradication of Helicobacter pylori with combination therapy of two antibiotics (often amoxicillin with clarithromycin) with a proton pump inhibitor (e.g. pantoprazol) during one week will heal and prevent peptic ulcer disease. 

Finally, it is universally accepted at present that Helicobacter pylori infection has a definitive ethiological role in peptic ulcer disease, and that erradication therapy is warranted in these clinical scenarios. The majority of therapeutic trials have included the application of triple therapy with proton pump inhibitors or ranitidine bismuth citrate, clarithromycin and either amoxycillin or metronidazol and is to date the treatment of choice. However, recent studies have reported antibiotic resistance which can be one reason for failure of treatment of Helicobacter pylori infection [101-103], and new treatment strategies are therefore Wellcome. Flavonoids, in addition to their gastroprotective activity previously commented, have been also shown to inhibit Helicobacter pylori growth in vitro. In this way, Beil et al. [50]... 

Patterson is referred to a gastroenterologist for endoscopy to examine the gastric mucosa. There are signs of inflammation in both the antrum and body of the stomach and an area of ulceration is visualized in the pylorus. Tests for Helicobacter pylori (H. pylori) are positive. Patterson was treated successfully with a course of antibiotics to eradicate the H. pylori infection and a proton pump inhibitor. 

Infection with the bacterium H. pylori is associated with ulcer development. Treatment of peptic ulcers may involve a course of antibiotics to eradicate this organism. Agents such as H2 (histamine) antagonists, for example ranitidine, and proton pump inhibitors, such as omeprazole, are also used to heal peptic ulcers. 

Clarithromycin is a commonly used macrolide antibiotic and is a regular part of regimens for the eradication of Helicobacter pylori, often in combination with a nitroi-midazole antibiotic as weU, in addition to a proton pump inhibitor. Variable rates of adverse events (4-30%) have been reported with clarithromycin. 

Drug-induced tubulointerstitial nephritides represent 1-10% of cases of acute renal failure and is characterized by infiltrates of mononuclear cells associated with tubular cell injury. A lot of drugs are incriminated, including antibiotics (P-lactams, sulfonamides, aminoglycosides, quinolones), antiepileptic drugs, diuretics, proton pump inhibitors, foscarnet and non-steroidal anti-inflammatory drugs [73]. Most often, withdrawal of the drug, with or without concomitant administration of steroids improves the renal functions. 

CT is a 47-year-old man who is about to be started on combination therapy for his H. py/or/-positive ulcer with antibiotics and either a proton pump inhibitor or an H2-receptor antagonist. Although proton pump inhibitors and H2-receptor antagonists are well tolerated, which of the following drug side effect combinations is most likely to occur during therapy ... 

Peptic ulcer disease is associated with Helicobacter pylori infection in 90% of patients with gastric and duodenal ulceration. Elimination of H. pylori infection with antibiotics heals the peptic ulcer and the associated symptoms. Combination therapy with antibiotics, anti-secretory agents, namely H2-receptor antagonists or proton pump inhibitors, and bismuth salts has significantly improved the clinical outcome of peptic ulcer disease. Not all strains of H. pylori cause peptic ulcer disease, and other factors are necessary for H. pylori colonization and disease to occur. Flagellated motile bacteria resist peristalsis and adhere to gastric epithelium in a highly specific manner. 

The selection of an HPeradication regimen should be based on efficacy, safety, antibiotic resistance, cost, and the likelihood of compliance. Treatment should be initiated with a proton pump inhibitor-based three-drug regimen. If a second course of HP therapy is required, the regimen should contain different antibiotics. 

Proton pump inhibitor-based three-drug regimens with two antibiotics (see Table 33-8) constitute first-line therapy for eradication of HP 1,5,36 meta-analysis of 666 studies indicates that PPI-based regimens that combine clarithromycin and amoxicillin, clarithromycin and metronidazole, or amoxicillin and metronidazole yield similar eradication rates (78.9% to 82.8%) nsing intent-to-treat analysis however, other studies suggest that the amoxiciUin-metronidazole combination is less effective. Eradication rates were improved when the... 

Gisbert JP, Khorrami S, Calvet X, et al. Meta-analysis Proton pump inhibitors vs. H2-receptor antagonists— their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther 2002 18 757— 766. 

Antibiotics Chronic infection with Helicobacter pylori is present in the great majority of patients with recurrent non-NSAID-induced peptic ulcers, and eradication of this organism greatly reduces the rate of recurrence of ulcer in these patients. The regimens of choice consist of a proton pump inhibitor plus a course of bismuth (Pepto-Bismol), tetracycline, and metronidazole or a course of amoxicillin plus clarithromycin. 

Metronidazole (in combination with tetracycline and bismuth) is one of the antibiotic regimens sometimes used to eradicate H pylori. The antibiotics are combined with a proton pump inhibitor or H, blocker. Amoxicillin and clarithromycin are also commonly used for this pur-... 

H. pylori is a major etiological factor in gastroduodenal disorders such as chronic gastritis, peptic ulcer, and gastric cancer. Therefore, the treatment and prevention of these diseases would be facilitated by its eradication. At present, triple therapies that comprise two antibiotics (clarithromycin and amphotericin B) and a proton pump inhibitor are used to eradicate H. pylori. However, strains that are resistant to antibiotics have appeared. In addition, antibiotic treatment is associated with serious side effects such as nausea, vomiting, and diarrhea. Therefore, the discovery of novel antibacterial agents that are highly effective and safe is badly needed for the treatment of H. pylori infection. 

It is a happy accident that the introduction H. pylori therapy and the introduction of the first proton pump inhibitor (PPI) omeprazole coincided. Instead of the expected battle of two controversial approaches to curing peptic ulcer disease - either H. pylori eradication with antibiotics or potent acid suppression by PPIs - they merged in a single strategy for healing ulcers. 

---